Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes

Blood

Volumn 98, Issue 4, 2001, Pages 958-965

  Raza, Azra ^a,b,c   Meyer, Peter ^a,b   Dutt, Diya ^a,b   Zorat, Francesca ^a,b   Lisak, Laurie ^a,b   Nascimben, Fabiana ^a,b   Du Randt, Morne ^a,b   Kaspar, Christopher ^a,b   Goldberg, Cathryn ^a,b   Loew, Jerome ^a,b   Dar, Saleem ^a,b   Gezer, Sefer ^a,b   Venugopal, Parameswaran ^a,b   Zeldis, Jerome ^a,b  

^a RUSH CANCER INSTITUTE   (United States)

^b CELGENE CORPORATION   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIDOXINE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BLAST CELL; BLOOD TRANSFUSION; BONE MARROW; CANCER CHEMOTHERAPY; CONSTIPATION; CYTOGENETICS; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUID RETENTION; HEADACHE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRELEUKEMIA; PRIORITY JOURNAL; RASH; REFRACTORY ANEMIA; SIDE EFFECT; SKIN TINGLING; THROMBOCYTE TRANSFUSION; VERTIGO;

EID: 0035883101     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.958     Document Type: Article

References (59)

1. Preisler HD. The treatment of myelodysplastic syndromes. Cancer. 1999;86:1893-1899.
2. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996;87:51-58.
3. Runde V, de Witte T, Arnold R, et al, on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 1998;21:255-261.
4. Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95:1188-1194.
5. Thompson JA, Gilliland DG, Prchal JT, et al, and the GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood. 2000;95:1175-1179.
6. Hansen PB, Penkowa M, Johnsen HE. Hematopoietic growth factors for the treatment of myelodysplastic syndromes. Leuk Lymphoma. 1998;28:491-500.
7. Santini V, Ferrini PR. Differentiation therapy of myelodysplastic syndromes: fact or fiction? Br J Haematol. 1998;102:1124-1138.
8. Miller K. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. Leuk Res. 1998;22(suppl 1):S13-S16.
9. Italian Cooperative Study Group for rHuEpo in myelodysplastic syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol. 1998;103:1070-1074.
10. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68-75.
11. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 1998;83:910-935.
12. Besa EC. Myelodysplastic syndromes: recent advances in the biology and therapy of this complex disease. Cancer Ther. 1998;1:52-63.
13. Ferrero D, Bruno B, Pregno P, et al. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res. 1996;20:867-876.
14. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996;10:40-42.
15. Visani G, Tosi P, Manfroi S, et al. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma. 1995;19:277-280.
16. Cheson BD. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res. 1998;22(suppl 1):S17-S21.
17. Hiddemann W, Jahns-Streubel G, Verbeek W, Wormann B, Haase D, Schoch C. Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities. Leuk Res. 1998;22(suppl 1):S23-S26.
18. Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999;17:2819-2830.
19. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(suppl 1):S21-S29.
20. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymphoma. 1990;2:415-418.
21. Hatfill SJ, Fester ED, Steytler JG. Apoptotic megakaryocyte dysplasia in the myelodysplastic syndromes. Hematol Pathol. 1992;8:87-93.
22. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
23. Raza A, Mundle S, Shetty V, et al. A paradigm shift in myelodysplastic syndromes. Leukemia. 1996;10:1648-1652.
24. Yoshida Y, Anzai N, Kawabata H. Apoptosis in myelodysplasia: a paradox or paradigm. Leuk Res. 1995;19:887-891.
25. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia. 1997;11:656-659.
26. Dar S, Mundle S, Andric T, et al. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol. 1999;62:90-94.
27. Mundle S, Venugopal P, Shetty V, et al. The relative extent and propensity of CD34+ vs. CD34cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol. 1999;69:152-159.
28. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839-845.
29. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20:891-900.
30. Mundle SD, Venugopal P, Pandav DV, et al. Indication of an involvement of interleukin-1β converting enzyme (ICE)-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes (MDS). Blood. 1996;88:2640-2647.
31. Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol. 1996;63:265-278.
32. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049-2054.
33. Allampallam K, Shetty V, Hussaini S, et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res. 1999;19:5323-5328.
34. List AF, Brasfield F, Heaton R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 1997;90:3364-3369.
35. Raza A, Venugopal P, Gezer S, et al. Pilot study of pentoxifylline and ciprofloxacin with or without dexamethasone produces encouraging results in myelodysplastic syndromes. In: Hiddemann W, Buchner T, Wormann B, et al, eds. Acute Leukemias VII: Experimental Approaches and Novel Therapies. Berlin, Germany: Springer-Verlag; 1998:42-51.
36. Raza A, Qawi H, Lisak L, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 2000;95:1580-1587.
37. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 2000;50:229-235.
38. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398-1401.
39. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427-1434.
40. Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol. 1992;81:346-352.
41. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol. 1996;33:150-162.
42. Carpani G, Rosti A, Vozzo N. T lymphocyte subpopulations in myelodysplastic syndromes. Acta Haematol. 1989;81:173-175.
43. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell recptor Vbeta profiles. Br J Haematol. 1998;102:1314-1322.
44. Biesma DH, van den Tweel JG, Verdnock LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548-1551.
45. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigenstimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160-167.
46. Pham-Huy C, Galons H, Voisin J, et al. In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A. Int J Immunopharmacol. 1997;19:289-296.
47. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
48. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
49. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol. 1996;81:219-223.
50. Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumor necrosis factor-α production by human alveolar macrophages. Respir Med. 1997;91:31-39.
51. Ching L-M, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumor agent 5, 6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumor necrosis factor-alpha and enhancement of anti-tumor activity. Br J Cancer. 1998;78:336-343.
52. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
53. Kenyou BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
54. Shimazawa R, Miyachi H, Takayama H, et al. Antiangiogenic activity of tumor necrosis factoralpha production regulators derived from thalidomide. Biol Pharm Bull. 1999;22:224-226.
55. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
56. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
57. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
58. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
59. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:2593-2602.